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Introduction: This study assessed the hypothesis that circulating human amylin
(amyloid-forming) cross-seedswith amyloidbeta (Aβ) in earlyAlzheimer’s disease (AD).
Methods: Evidence of amylin-AD pathology interaction was tested in brains of 31
familial AD mutation carriers and 20 cognitively unaffected individuals, in cere-
brospinal fluid (CSF) (98 diseased and 117 control samples) and in genetic databases.
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For functional testing, we genetically manipulated amylin secretion in APP/PS1 and
non-APP/PS1 rats.
Results: Amylin-Aβ cross-seeding was identified in AD brains. High CSF amylin lev-
els were associated with decreased CSF Aβ42 concentrations. AD risk and amylin
gene are not correlated. Suppressed amylin secretion protected APP/PS1 rats against
AD-associated effects. In contrast, hypersecretion or intravenous injection of human
amylin inAPP/PS1 rats exacerbatedAD-likepathology throughdisruptionofCSF-brain
Aβ exchange and amylin-Aβ cross-seeding.
Discussion:These findings strengthened thehypothesis of circulating amylin-AD inter-
action and suggest thatmodulation of blood amylin levels may alter Aβ-related pathol-
ogy/symptoms.
KEYWORDS
amylin, amyloid, familial Alzheimer’s disease, islet amyloid polypeptide, sporadic Alzheimer’s dis-
ease
1 INTRODUCTION
Disease course-modifying therapeutic targets remain the highest
unmet needs in Alzheimer’s disease (AD),1 a brain disorder that afflicts
more than 5.7 million Americans of all ages, a number projected to
triple by 2050. Given that deterioration of cognition and cerebral accu-
mulation of amyloid beta (Aβ) and tau tangles are characteristics of AD
dementia, in brain imaging and at autopsy,2 current therapeutic strate-
gies are aimed at interrupting cerebral Aβ plaque formation. Alterna-
tive approachesmay involvemodulation of blood levels of proteins that
cross-seed with Aβ. Recent data from multiple research teams3–8 sug-
gest that one potential modifier of AD pathology may be circulating
amylin, an amyloidogenic pancreatic hormone.9
Thepancreatic hormoneamylin (or islet amyloidpolypeptide [IAPP])
normally participates in the regulation of satiation through signaling
pathways within the hypothalamus.10 Recent analyses of plasma data
from Alzheimer’s Disease Neuroimaging Initiative and in serum data
from the Texas Alzheimer’s Research and Care Consortium identified
circulating pancreatic amylin as a mediator of age-specific effects on
dementia severity.8 Brain parenchyma and microvasculature in indi-
viduals with late-onset sporadic AD (sAD) have amylin deposits and
mixed amylin–Aβ plaques.3–7 Aggregated amylin with similar molecu-
lar weights were identified in matched plasma and brain tissues from
humans with sAD3 suggesting that toxic amylin species include circu-
lating aggregated amylin.
Because amylin is co-secretedwith insulin,11 conditionswith insulin
dysregulation, such as insulin resistance and type 2 diabetes, may
increase the amount of amylin crossing from blood to the central ner-
vous system.High circulating amylin levels in plasma and cerebrospinal
fluid (CSF)12 could increase the risk for AD. Even if amylin secretion is
normal in AD, amylin may be harmful to the brain by interacting with
Aβ pathology. Importantly, insulin secretion is to some extent modifi-
able, and therapeutic agents to block amyloidogenicity of circulating
amylin13 may be ameans of reducing amylin–Aβ cross-seeding.
Because individuals with early-onset familial forms of AD will
develop AD pathology,14 evidence of amylin–Aβ cross-seeding in the
brains of persons with familial AD (fAD) could strengthen the hypoth-
esis of a role of circulating amylin in AD pathology. We therefore
analyzed brains of individuals inheriting mutations in the amyloid
precursor protein (APP) and presenilin 1 (PS1) for immunochemical
evidence of amylin interaction with areas of AD-related histopathol-
ogy (Aβ and tau deposits). To testwhether circulating amylin is involved
in early AD pathological processes, we analyzed the amylin–Aβ42
relationship in CSF from humans with AD pathologic change and a
diagnosis of mild cognitive impairment (MCI) or dementia, and in
CSF from cognitively unimpaired (CU) individuals. To directly address
the potential for modulation of circulating amylin levels as means to
alter AD-related pathology/symptoms, we manipulated the pancreatic
secretion of amylin through gene suppression and overexpression in
APP/PS1 rats and infused human amylin intravenously inAPP/PS1 rats.
Our work provides a basis for additional studies to validate circulating
amylin as a potential therapeutic target for AD.
2 METHODS
Detailed methods are included in Appendix A in supporting informa-
tion.
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2.1 Human studies
Institutional review board approval and informed consent were
obtained prospectively at the institutions participating in this
study. Formalin fixed and frozen temporal cortex tissue from
31 fAD mutation carriers were provided by the Queen Square
Brain Bank for Neurological Disorders at UCL Queen Square
Institute of Neurology (United Kingdom) and King’s College Lon-
don (United Kingdom). Both formalin fixed and frozen tissue
was available for 14 brains. Brain tissue samples from 20 age-
matched CU individuals were obtained from the AD Center at
the University of Kentucky (USA). AD Centers at the University
of Kentucky, University of Washington (USA), Wake Forest Uni-
versity (USA), and University of Gothenburg (Sweden) provided
the CSF samples for this study (98 diseased and 117 control
samples). Details on patients and sample size for each analy-
sis are summarized in Appendix B, Tables B.1-B.3 in supporting
information.
2.1.1 Immunochemical analyses
Frozen and formalin fixed brain tissues were processed as previously
described.3,7 Brain amylin andAβ concentrationsweremeasured using
the enzyme-linked immunosorbent assay (ELISA) for amylin (EZHA-
52K, Millipore) and Aβ42 (KHB3441, Thermo Fisher). Brain amylin
deposition and interaction with AD-related histopathology were
assessed by immunohistochemistry (IHC) and confocal microscopy.
For IHC analysis, the immunoreactivity intensity signals of amylin and
Aβ were deconvoluted using ImageJ. Details on antibodies, reagents,
and image analysis are included in Appendix A.
2.1.2 CSF amylin and CSFAβ42 levels
Observer-blind measurement of CSF amylin levels was per-
formed by using amylin ELISA (EIA-AMY; RayBiotech). The
results were communicated to the AD Centers providing the
samples for assessing the relationships with CSF Aβ42 and cog-
nitive function of the individuals providing the sample. CSF
Aβ42 levels were measured with the INNO-BIA AlzBio3 mul-
tiplex assay (FujiRebio) at the AD Centers providing the sam-
ples.
2.1.3 Genomic analysis
Databases from the International Genomics of Alzheimer’s Project
(IGAP; n= 17,008 AD cases and n= 13,154 controls) andHealthy Exo-
somes (HEX; n= 331 AD cases and n= 468 controls) were used to test
the association of common and rare amylin gene variants with the risk
for AD.
Research in Context
1. Systematic review: Although the association between
dysregulationof circulating amylin (islet amyloidpolypep-
tide [IAPP]) andAlzheimer’s disease (AD) pathology is not
yet aswidely studied as other aspects ofADbiology, accu-
mulating evidence frommultiple research teams describe
amylin–amyloid beta (Aβ) cross-seeding in brains of indi-
viduals with sporadic AD. One study reported that high
blood amylin and high cerebrospinal fluid (CSF) amylin
correlate in sporadic AD.
2. Interpretation of results: Early AD processes may affect
the central regulation of pancreatic amylin leading to
abnormal circulating amylin and amylin–Aβ cross-seeding
in the brain.
3. Future directions: This study provides a basis for addi-
tional hypothesis-driven research and evidence-based
validation studies to help understand: the triggers of
amylin–Aβ interaction and whether reducing amylin
dyshomeostasis could slow the progression of AD, the
impact of peripheral amylin dyshomeostasis on Aβ clear-
ance across the blood-brain barrier, and effects of circu-
lating amylin levels on CSF–brain Aβ exchange in human
AD.
2.2 Animal studies
This investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the U.S. National Institutes of Health
(NIH Publication No. 85-23, revised 2011) and was approved by
the Institutional Animal Care and Use Committees at University of
Kentucky.
2.2.1 Human amylin expression in APP/PS1 and
non-APP/PS1 rats
Rats that overexpress (three-fold) human amylin in the pancreas
(HIP rats) and develop brain amylin pathology6,7,15 were crossed
with APPSwe/PS1ΔE9 rats (TgF344-19 rats) that develop AD-like
pathology16 to generate APP/PS1/HIP rats (amylin-Aβ model rats).
Because rodent amylin is non-amyloidogenic,9 APP/PS1 littermates
served as controls for the amyloidogenic human amylin effects. HIP
and wild-type (WT) rats from the same litters as APP/PS1/HIP and
APP/PS1 ratswere used to assess the effects of brain amylin pathology,
in the absence of APPSwe/PS1ΔE9 mutations. F2 litters were used in
experiments. Male rats were used, because amylin dyshomeostasis
develops earlier in male (≈12 months) than in female (> 18 months)
rats.7
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2.2.2 Suppressed amylin expression in APP/PS1
rats
To test whether suppressing amylin secretion reduces AD-related neu-
rologic deficits, we crossed APP/PS1 rats with amylin knockout rats
(AKO rats) to generate APP/PS1/AKO rats that lack the amylin gene.
AKO rats were previously characterized.7 Rats from the F3 generation
were used in these experiments to ensure the homozygosity of AKO
genotype in the APP/PS1/AKOmodel.
2.2.3 Immunochemical detection of human versus
rat amylin
Because homozygous HIP and APP/PS1/HIP rats have increased mor-
tality rates, we used heterozygous rats that express both human and
rat amylin. ELISA and anti-amylin antibody sensitivities/affinities are
higher for rat versus human amylin (technical evaluation in Appendix
A).
3 RESULTS
3.1 Circulating amylin cross-seeds with Aβ in
brains of PS1 and APP mutation carriers
To test the hypothesis (Figure 1A) that amylin secreted from the pan-
creas interactswith fADpathology, brain tissue from fADmutation car-
riers and CU individuals were analyzed using ELISA, IHC, and confocal
microscopy. Amylin ELISA revealed that brains of PS1 mutation carri-
ers had higher amylin levels compared to CU individuals (Figure 1B).
Increased brain amylin concentrations were associated with greater
Aβ42 levels inPS1 versusCUbrains (ELISA; Figure 1C). A nonsignificant
increased brain accumulation of amylin was also identified in APP ver-
sus CU brains (P= 0.09; Figure 1B), which is similar to the tendency for
higher Aβ42 in this group (P= 0.07; Figure 1C). Overall, increased brain
amylin levels correlated strongly (R2= 0.40, P < 0.01) with increased
brain Aβ42 levels in fAD (Figure 1D), whereas the amylin–Aβ relation-
ship was variable in CU brains (Figure 1E).
IHC co-staining with anti-amylin and anti-Aβ antibodies in fAD
brain sections detected distinct amylin and Aβ plaques and mixed
amylin–Aβ plaques (Figure 1F-M). Some plaques stained positive
for amylin adjacent to Aβ deposition (Figures 1H and 1I), had lay-
ered amylin–Aβ compositions with amylin-positive cores (Figure 1J-L)
or formed intercalated amylin–Aβ deposits as shown in Figure 1M.
For deconvolution and analysis of amylin immunoreactivity inten-
sity signals on IHC images, pancreatic tissue from a patient with
type 2 diabetes served as positive control for amylin deposition
(Figure S1A in supporting information). The IHC analysis detected
amylin in about one third of the plaques in fAD brains (Figure
S1B). CU brains have sporadic amylin deposits (Figure S1C); how-
ever, amylin–Aβ cross-seeding is lower in CU versus fAD brains
(Figure 1C).
In fAD brains, amylin immunoreactivity was detected in neuronal
soma (Figures 1F and 1G; arrowheads; 26 of 27 patients) and neu-
ritic plaques (Figure 1H-M, 16 of 27 patients). In some amylin–Aβ neu-
ritic plaques, immunostaining showed the presence of amylin in small
proteinaceous fragments (Figures 1F and 1G; arrows). Confocal micro-
scopic analysis of areas containing amylin-positive neurons revealed
no overlap between the immunoreactivity signals for amylin and p-tau
(Figure S2A-S2C in supporting information) suggesting distinct amylin
and tau pathologies.
To test whether mixed amylin–Aβ plaques have biochemical char-
acteristics of amyloid, brain slices were triple-stained with Thioflavin
S and anti-amylin and anti-Aβ antibodies. Confocal microscopy analy-
sis identified Thioflavin S–positive areaswithin the Aβ deposits (Figure
S2D) and in the amylin cores ofmixed amylin-Aβplaques (Figure1N-Q).
Amylin amyloid plaques have similar structures to those formed in sAD
(Figure S2E).
In sAD brains, amylin was identified within the arteriole wall, as
part of cerebral amyloid angiopathy (CAA).3,4 Post mortem histological
reports included comorbid CAA in many fAD brains from this cohort
(Table B.4). Histological evidence of cerebral small vessel disease was
reported also in CU brains (Table B.4). We tested the association
of brain amylin accumulation with blood-brain barrier (BBB) leak by
assessing the brain uptake of immunoglobulins (IgG). Analysis of anti-
IgG staining in brain sections revealed variable levels of compromised
BBB (Figure S3 in supporting information) in both fAD and CU brain
groups. IHC analyses of serial sections for amylin, amylin–Aβ cross-
seeding, and Congo red staining (Figure 1R-U) suggest that amylin is
part of CAA. This was further confirmed by confocal microscopy analy-
sis of brain sections triple-stained for amylin, Aβ, and α-smoothmuscle
cell actin (Figure 1V-Y). Brain amylin pathology is summarized in Table
B.5.
Analyses of the association of common and rare amylin gene vari-
ants with the risk of developing AD revealed no statistically signifi-
cant differences (Table B6). Taken together, our results indicate that
circulating amyloid-forming amylin secreted from the pancreas inter-
acts with fAD pathology through mechanisms that are not linked to a
genetic predisposition andmay involve amylin as a part of CAA.
3.2 High CSF amylin levels are associated with
decreased CSF Aβ42 levels in early AD
The order of biological changes in fAD begins with deposition of
amyloid, followed by neurodegenerative changes (assessed from CSF
biomarkers) and cognitive decline.17 To testwhether amylin homeosta-
sis in the central nervous system may change in early sAD, we investi-
gated the relationships between CSF amylin and CSF Aβ42, a validated
AD biomarker,2 in CU, MCI, and sAD dementia CSF samples. The aver-
age CSF levels of both amylin and Aβ42 are associated with the cogni-
tive status (Figure 2A-B). Decreased CSF Aβ42 levels correlated with
decreased CSF amylin levels in sAD (Figure 2C). In MCI, however, CSF
amylin and Aβ42 levels were inversely correlated, with lower Aβ42 lev-
els being associated with higher amylin levels (Figure 2D). Both CSF
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F IGURE 1 Brain amylin–amyloid beta (Aβ) relationship in PSEN1 and APPmutation carriers. A, Schematic amylin–Aβ cross-seeding
hypothesis. B-E, Amylin and Aβ42 levels and the relationship between amylin and Aβ42 concentrations in temporal cortex specimens from PS1 and
APPmutation carriers (n= 11 and n= 7, respectively) and cognitively unaffected individuals (CU; n= 12). F-M, Representative images of
immunohistochemistry analysis using anti-amylin (brown) and anti-Aβ (green) antibodies on temporal cortex slices from familial Alzheimer’s
disease (fAD) brains. Amylin deposition in neurons (F, G; arrowheads) or forming homogenous plaques (F, G; arrows; H, I) and amylin–Aβ plaques
(J-M) are shown. N-Q, Confocal microscopic analysis of a fAD brain section triple stainedwith Thioflavin S (ThioS, green; N), anti-amylin antibody
(red; O), and anti-Aβ antibody (magenta; P). R-U, representative images of consecutive fAD brain sections stained with Congo red (R), anti-Aβ (S),
anti-amylin (T), or a combination of anti-amylin (brown) and anti-Aβ (green; U) antibodies. V-Y, Confocal microscopic analysis of a fAD brain section
triple stained with anti-amylin antibody (green; V), anti-Aβ antibody (red;W) and anti-α smoothmuscle cell (SMC) actin antibody (blue; X). Type of
PS1 or APPmutation is labeled on each image; three sections/brain, n= 27 fAD brains and n= 27 CU brains. Scale bars, 50 μm (F-M, R-U), 10 μm
(N-Q) and (V-Y). Data aremeans± standard error of themean; P≤ 0.01 **, P≤ 0.0001 ****; one-way analysis of variance with Dunnett’s multiple
comparisons test (B, C); correlation analysis (D, E)
amylin and Aβ42 levels were highly variable in the CU individuals (Fig-
ure 2E).
These results suggest that increases in CSF amylin and decreases in
CSF Aβ42 levels may be characteristic of early cognitive change in the
MCI stage of sAD, which needs to be further evaluated in a larger sam-
ple with longitudinal characterization of the cohort.
3.3 Genetically suppressed amylin secretion in
APP/PS1 rats protects against AD effects
To address the potential for altering AD-related pathology/symptoms
through modulation of the blood amylin level, we genetically manipu-
lated amylin secretion in APP/PS1 and non-APP/PS1 rats by pancreatic
overexpression of human amylin (3-fold) or amylin gene deletion. Rep-
resentative genotyping results for newly generated transgenic rats are
shown in Figure S4A-S4C in supporting information. Study design and
study time points are described in Figure 3A-C.
Although APP/PS1/HIP and HIP rats overexpress human amylin
throughout their lives, their plasma levels of amylin (combined rat and
human amylin) increase with aging (> 12 months of age), whereas
there is no significant change of plasma levels of amylin (rat amylin
only) in APP/PS1 andWT littermates (Figures 3D and 3E). Plasma from
APP/PS1/HIP rats had increased amylin immunoreactivity intensity
signals at high molecular weight bands (> 3.9 kDa; monomeric amylin)
compared to plasma from APP/PS1 littermates (Figure S5 in support-
ing information). The results are consistent with previous reports in
HIP versus WT rats7,15,18 and reflect the constructive validity of the
human amylin-expressing rats. We interpret the presence of aggre-
gated amylin in the systemic circulation as a possible sign of amylin
dyshomeostasis that may be triggered by different conditions, includ-
ing amylin hypersecretion (common in prediabetes).7 APP/PS1/HIP
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F IGURE 2 Cerebrospinal fluid (CSF) amylin–amyloid beta (Aβ)42 relationship in Alzheimer’s disease (AD), mild cognitive impairment (MCI),
and cognitively unaffected (CU) humans. A, B, Levels of CSF amylin (A) and CSF Aβ42 (B) in patients with sporadic AD (sAD, n= 28); individuals with
MCI (n= 70), and in CU individuals (n= 117). C-E, Correlation analysis of CSF amylin levels versus CSF Aβ42 levels in patients from (A, B). Data are
presented as box andwhisker plot (A, B) and as individual values (C-E); P≤ 0.05 *, P≤ 0.01 **, P≤ 0.001 ***, P≤ 0.0001 ****; two-tailed, unpaired t
test (A, B); correlation analysis (C-E)
ratswith high plasma levels of amylin (combined rat and human amylin)
had greater behavior deficits (Figure 3D and Figure S6A-S6C in sup-
porting information), which worsened at a higher rate with aging than
in APP/PS1 littermates expressing only rat amylin (Figure 3F). Sim-
ilarly, cognitive performance declined faster in aged HIP rats with
high plasma amylin levels (combined rat and human amylin) than in
WT littermates (Figures 3E and 3G and S6D-S6F). The neurological
score-plasma amylin relationship in HIP rats versus WT littermates
(Figure 3E) suggests that high blood amylin levels affect neurological
score in the absence of genetic determinants of AD pathology.
The Novel Object Recognition (NOR) test in HIP rats (Figure S6D in
supporting information) suggests that amylin dyshomeostasis impairs
short-term memory with age in the absence of AD-like pathology. We
therefore tested whether suppressed amylin expression in APP/PS1
rats alters the results of the NOR task. APP/PS1 with the amylin gene
deleted (APP/PS1/AKO rats) had lower plasma amylin and less severe
memory retention deficits at age 16 months compared to APP/PS1 lit-
termates (Figure 3H-J).
Our results suggest the following: (1) rats that are prone to develop
mixed amylin–Aβ pathology have greater neurological deficits com-
pared toAPP/PS1 rats; (2) highblood amylin levels affect brain function
in the absenceof genetic determinants ofADpathology inHIP rats; and
(3) suppressionof amylin secretionprovides a sustainedprotection lon-
gitudinally against recognition memory deficits in APP/PS1/AKO rats,
compared to APP/PS1 rats.
3.4 High blood amylin disrupts CSF–brain Aβ
exchange by amylin–Aβ cross-seeding in brain
Next, we tested amylin–Aβ interaction in aged APP/PS1/HIP and
APP/PS1 littermates using IHC co-staining with anti-amylin and anti-
Aβ antibodies in brain slices (Figure 4A-E). The density of plaques
(amylin, Aβ, and amylin–Aβ plaques) was higher in 16-month-old
APP/PS1/HIP rat brains compared to controls (Figure 4F). Amylin
formed the protein core of Aβ plaques in both groups (Figure 4A-D);
however, surface area covered by mixed amylin–Aβ deposits was
higher in APP/PS1/HIP brains compared to that in APP/PS1 rat brains
(Figures 4G and 4H). Non-APP/PS1 rats expressing human amylin (ie,
the HIP rats) had brain amylin deposition in the absence of AD muta-
tions (Figure S7A-S7B in supporting information). In contrast, WT rats
had no cerebral amylin plaques suggesting that rat amylin does not
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F IGURE 3 Behavior deficits in APP/PS1 and non-APP/PS1 rats with genetically manipulated amylin secretion. A-C, Schematic summary of rat
models generated for this study and time points of behavior andmolecular analyses. Genetic manipulation of circulating amylin was performed in
rats with andwithout Alzheimer’s disease (AD)-like pathology through transgenic expression of human amylin in the pancreas (red color code, A)
and by deletion of the amylin gene (light blue color code, B). The time points for behavioral studies were chosen based on previous reports that
amylin dyshomeostasis develops at≈12months of age in human amylin expressing rats7,15 and that amyloid beta (Aβ) pathology is developed in
APP/PS1 rats at about 16months of age16 (C). D-G, Longitudinal neurological scores of cognitive function (assessed fromNovelObject Recognition
andwater maze performance tests) versus plasma amylin levels (both rat and human amylin; D, E) and versus age (F, G) in APP/PS1/HIP versus
APP/PS1 rats, and HIP versus wild-type (WT) rats (n= 10 rats/group). Data for individual tests are shown in Figure S6 in supporting information. H,
Plasma amylin levels in APP/PS1 rats versus APP/PS1 rats with suppressed amylin expression (APP/PS1/AKO rats) at 16months of age. I, Novel
object recognition in APP/PS1 rats versus APP/PS1/AKO rats at 8, 12, and 16months of age (n= 10 rats/group). J, Longitudinal neurological scores
of cognitive function in APP/PS1 versus APP/PS1/AKO rats (n= 10 rats/group). Data aremeans± standard error of themean. P≤ 0.05 *, P≤ 0.01
**, *, P≤ 0.001 ***; correlation analysis (D, E); two-way analysis of variance with Sidak post hoc (F, G, J); two-tailed, unpaired t test (H, I)
formcerebral plaques innon-APP/PS1 rats that expressonly rat amylin.
In addition to amylin-core Aβ plaques, APP/PS1/HIP rat brains had
amylin accumulation in neuronal soma (Figure 4E) mirroring our find-
ings in fADbrains (Figure1).Cerebral vascular depositionof amylinwas
identified in APP/PS1/HIP and HIP rats, but not APP/PS1 andWT rats
(FigureS7C-S7F), indicating apossible relationshipbetweenhighblood
amylin levels and cerebral vascular amylin deposition. Pancreatic tissue
from rats in all groupswere used as controls for amylin immunoreactiv-
ity signals in the brains (Figure S8A-S8E in supporting information).
Higher plasma levels of amylin (combined human and rat amylin)
in APP/PS1/HIP versus APP/PS1 rats are associated with lower CSF
Aβ levels (Figure 4I) and more cerebral plaques (Figure 4F). Amylin
secreted from the pancreas accumulated in the brain (Figure 4J) and
cross-seededwithAβ (Figure 4G)without significant change of theCSF
concentration of amylin (combined human and rat amylin; Figure 4K).
These results suggest that increased circulating amylin levels may
alter CSF–brain Aβ exchange through amylin–Aβ cross-seeding in the
brain.
3.5 Suppressed amylin secretion decreases
amyloid density in plaques
Cross-seeding between rat amylin and Aβ in APP/PS1 rat brains
was unanticipated, because rodent amylin does not form amyloid.9
In contrast to the human brain (which lacks amylin mRNA3), some
rodent brain cells appear to secrete amylin10 that may promote
direct amylin–Aβ interaction in APP/PS1 rats. We therefore tested
whether genetically suppressed amylin secretion in APP/PS1 rats
is associated with decreased cerebral amylin–Aβ plaque formation.
Essentially, APP/PS1/AKO rats with the amylin gene deleted lacked
amylin–Aβ cross-seeding in the brains, whereas APP/PS1 littermates
had amylin-core Aβ plaques (CP) in brain sections (Figure 5A-G).
Decreased amylin–Aβ cross-seeding in APP/PS1/AKO rat brains
correlated with lower amylin immunoreactivity intensity signal
in pancreatic tissues (Figure S8E), plasma (Figure 3H), and brain
homogenates (Figure 5H) from these rats, compared to APP/PS1
rats.
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F IGURE 4 Amylin–amyloid beta (Aβ) cross-seeding and impaired cerebrospinal fluid (CSF)–brain Aβ exchange by high blood amylin levels
(both rat and human amylin) in APP/PS1 rats. A-E, Representative immunohistological images of co-staining with anti-amylin (brown) and anti-Aβ
(green) antibodies in brain sections from 16-month-old APP/PS1/HIP rats (A, C, E) and APP/PS1 rats (B, D; n= 5 rats/group). Amylin–Aβ plaques
(A-D) and amylin depositions within neurons (E) are shown. F, Analysis of total plaques including Aβ plaque, amylin plaque, and amylin-core Aβ
plaque depositions in APP/PS1 and APP/PS1/HIP rat brains, assessed from immunohistological images (n= 5 rats/group; data were normalized to
total imaging area). G, H, Relative distribution of amylin, Aβ, and amylin–Aβ in plaques in the graymatter of APP/PS1/HIP rat brains (G; n= 5) and
APP/PS1 rat brains (H; n= 5). I-K, CSF total Aβ (I; n= 6 rats/group), brain amylin (Triton-soluble fractions of tissue homogenate; n= 5 rats/group; J),
and CSF amylin (K; n= 6 rats/group) levels in APP/PS1/HIP versus APP/PS1 rats at 16months of age. Scale bars, 200 μm (A, B), 50 μm (C-E). Data
aremeans± standard error of themean; P≤ 0.05 *, P≤ 0.01 **, P≤ 0.001 ***; two-tailed, unpaired t test
F IGURE 5 Decreased brain amylin amyloid-core plaques in APP/PS1 rats with genetically suppressed amylin secretion. A-F, Representative
images of immunostaining for amylin (brown) and amyloid beta (Aβ) (green) in brain tissues from 16-month-old APP/PS1/AKO rats (A-C) and
APP/PS1 littermates (D-F). Arrows indicate amylin-core Aβ plaques (CP). G, Counts of amylin-core Aβ plaques in APP/PS1 and APP/PS1/AKO rat
brains assessed from immunohistological images (n= 5 rats/group; data were normalized to total imaging area). H, I, Amylin and Aβ levels in brain
homogenates from 16-month-old APP/PS1/AKO rats and APP/PS1 littermates. J, Counts of Aβ plaques in the same APP/PS1 and APP/PS1/AKO
rat brains as in (G; n= 5 rats/group). Scale bars, 50 μm (A, B, D, E), 200 μm (C, F). Data aremeans± standard error of themean. P≤ 0.05 *; P≤ 0.01
**; two-tailed, unpaired t test
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F IGURE 6 Circulating aggregated amylin cross-seeds with brain amyloid beta (Aβ) in young APP/PS1 rats. A, Experimental protocol for
intravenous amylin infusion in rats. B, Plasma amylin levels in APP/PS1 rats intravenously infused with human amylin and agematched APP/PS1
control rats at baseline and after injections (n= 5 rats/group). C, D, Immunohistological analysis with anti-amylin (brown) and anti-Aβ (green)
antibodies showing amylin-Aβ plaques (C; arrow) and amylin accumulation in neurons (D; circles) of APP/PS1 rats intravenously infused with
human amylin and age-matched APP/PS1 control rats (n= 3 rats/group). E,Western blot analysis of amylin and Aβ levels in the brain homogenate
extracted using phosphate-buffered saline or sodium dodecyl sulfate fromAPP/PS1 rats intravenously infused with human amylin and
age-matched APP/PS1 control rats (n= 3-4 rats/group). F, Schematic summary of the results. Circulating aggregated amylin affects brain and
cerebrospinal fluid (CSF) Aβ levels via brain amylin accumulation and amylin-Aβ cross-seeding. Amylin gene deletion in APP/PS1 rats blocks amylin
accumulation in the brain and amylin–Aβ cross-seeding, providing protection against AD-associated effects. Scale bars, 50 μm (C, D). Data are
means± standard error of themean; two-tailed, paired t test (B), P≤ 0.05 *; two-tailed, unpaired t test (E)
It is worth noting that lack of endogenous rat amylin secretion in
APP/PS1/AKO rats appears to not increase brain Aβ concentration
(measured by total Aβ ELISA) in the APP/PS1/AKO rat brains, com-
pared to APP/PS1 littermates (Figure 5I). The extent of Aβ pathol-
ogy was similar in APP/PS1 and APP/PS1/AKO rats (Figure 5J). Fur-
thermore, western blot analysis of brain homogenates from APP/PS1
versus APP/PS1/AKO rat brains suggests that suppressed circulating
amylin does not increase solubleAβ levels in the brain (Figure S9 in sup-
porting information).
3.6 Circulating aggregated amylin accelerates
amylin–Aβ cross-seeding in the brain
Greater pathological processes in brains of aged APP/PS1/HIP versus
APP/PS1 rats were associated with circulating aggregated amylin (Fig-
ure S5), and this was also the case in plasma from aged HIP versusWT
rats.7,15,18 To assess the impact of circulating aggregatedhumanamylin
(amyloid forming) on early AD pathological processes, young APP/PS1
rats (age 7 months), studied before the development of Aβ pathology
(which occurs at age ≈16 months), were injected intravenously with
pre-aggregated human amylin (Figure 6A; the schematic schedule of
the treatment). Amylin was infused for 2 months at a dose that only
slightly elevated the plasma amylin level (Figure 6B). The aggregation
status/size distribution of injected amylin is shown in Figure S10 in
supporting information. At the conclusion of the infusion regimen,
amylin-core Aβ plaques were detected in treated (Figure 6C) but not
in untreated rats. Brains of APP/PS1 rats intravenously infused with
human amylin also showed neuronal amylin deposition (Figure 6D),
consistent with our findings in APP/PS1/HIP rats (Figure 4E) and
human fAD brains (Figure 1F-G), and higher soluble amylin and Aβ
levels by western blot analysis of brain homogenates (Figure 6E and
Figure S11 in supporting information).
The results support the hypothesis that circulating aggregated
amylin (amyloid-forming) has a great effect on the cerebral plaque
structure by promoting amylin–Aβ cross-seeding.
4 DISCUSSION
This study shows that circulating amyloid-forming amylin secreted
by the pancreas cross-seeded with Aβ in brain parenchyma and blood
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vessel walls in PSEN1 and APP mutation carriers. Increases in CSF
amylin and decreases in CSF Aβ42 levels appeared in the setting
of early cognitive change in the MCI stage of sAD. In APP/PS1
rats, genetically suppressed amylin secretion protected against AD
effects, whereas hypersecretion of human amylin accelerated AD-like
pathology through (at least in part) circulating aggregated amylin.
At the molecular level, circulating aggregated amylin correlated with
disrupted CSF–brain Aβ exchange and amylin–Aβ cross-seeding in
the brain. Intravenously infused aggregated human amylin induced
amylin–Aβ cross-seeding in young APP/PS1 rats before the devel-
opment of Aβ pathology. These results (summarized in Figure 6F)
demonstrate a role of circulating aggregated amylin in early AD and
suggest that restoring amylin homeostasis may reduce AD pathology.
Amylin dysregulation contributes to type 2 diabetes.9,19 Aβ cross-
seeds with amylin in the pancreatic islets5 suggesting that AD-
related pathological processes may affect β-cell function. Because the
hypothalamus regulates pancreatic β-cell function20 and is affected
by AD pathology, it was hypothesized that AD-related pathologi-
cal processes may impair central signaling pathways that regulate
amylin and insulin secretion.21 Our results emphasize the need to
elucidate the temporal sequence of amylin- and early AD–mediated
pathological events in the brain and peripheral tissues, as well as the
impact of AD pathology on central function of amylin as a satiation
hormone.10
In sAD, brain amylin pathology was explained by
hyperamylinemia,22 as it coincides with insulin resistance and type 2
diabetes, which are risk factors for sAD.23,24 We did not anticipate
amylin dyshomeostasis in fAD, given the earlier onset of disease with
reduced age-dependence of amyloid pathology. The triggers of amylin
dyshomeostasis in fAD mutation carriers has yet to be elucidated. It
is intriguing that the brain amylin levels are higher in PSEN1 versus
APP mutation carriers. Presenilins are present in pancreatic β-cells;25
whether mutant presinilin is a link between amylin dyshomeostasis
and fAD awaits further investigation.
In non-APP/PS1 rats, hypersecretion of human amylin impaired
brain function in the absence of AD pathology. In APP/PS1 rat brains,
rat amylin cross-seededwithAβ (anunanticipated result),whereas sup-
pressed amylin secretion protected against AD effects. These results
directly address the potential for modulation of circulating amylin as
a means to alter AD pathology. It has been reported that injection of
the pancreatic peptide amylin potently reduces behavioral impairment
and brain amyloid pathology in murine AD models26 and proposed
that amylin protects against AD effects in humans.27 If amylin low-
ers Aβ pathology, we then should expect that genetically suppressed
amylin gene in APP/PS1 rats will exacerbate AD pathology and behav-
ior deficits, whereas overexpressing amylin will slow disease progres-
sion. Our results demonstrated the opposite and are consistent with
data showing that intracerebroventricular human amylin administra-
tion in murine AD models promotes robust amylin–Aβ cross-seeding,
accelerating AD pathology;28 and pancreatic expression of amyloid-
forming human amylin in murine ADmice exacerbate cerebral amyloid
burden through cumulative diabetogenic effects of the coexpressed
human amylin and Aβ.29
There are limitations to our study of fAD brain specimens and
human CSF. We were not able to track possible glucose dysregula-
tion in patients. Neither effects of anti-AD treatments nor specific
forms of anti-depressant drugs given to individual patients, which
may affect pancreatic function including amylin and insulin secretion,
were available. The CSF amylin–Aβ42 relationship needs to be fur-
ther tested in a larger sample with longitudinal characterization of the
cohort.
In conclusion, finding amylin–Aβ cross-seeding in fADmutation car-
riers is of interest because: (1) a role of pancreatic amylin in familial AD
was previously unknown, (2) there is accumulating evidence showing
brain amylin dyshomeostasis in themuchmoreprevalent sporadic form
of AD, and (3) development of anti-amylin drugs may improve the lives
of fADmutation carriers and slow the progression of sporadic AD.
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